The successful weight loss trial of the amycretin pill pushed Novo Nordisk past Tesla in market value to $604 billion, increasing investor interest in innovative solutions for major health issues like obesity.
Tags: Novo Nordisk
Novo Nordisk CEO to Testify Before Senate After Sanders' Subpoena Threat Over Drug Pricing
Novo Nordisk CEO Lars Fruergaard Jørgensen will testify before the Senate following Sen. Bernie Sanders' threat to subpoena the company over the pricing of diabetes drug Ozempic and obesity drug Wegovy.
Telehealth Startup Ro Develops Online Tracker to Combat Wegovy Shortages Amid Weight-Loss Drug Demand
Telehealth startup Ro has launched a free online tracker to help patients and doctors locate in-stock weight-loss drugs like Wegovy amid national shortages, providing real-time availability and the option to report outages to the FDA.
Amgen Challenges Novo Nordisk, Eli Lilly in Weight Loss Drug Market as Investors Flock for Next Obesity Drug Payout
Amgen witnessed an impressive 12% surge in its shares on Friday, marking its most substantial single-day increase in nearly 15 years.
Gates Foundation Partners With Novo Nordisk and Wellcome Trust in $300 Million Initiative to Advance Global Health Research
The Bill & Melinda Gates Foundation, Novo Nordisk Foundation, and Wellcome Trust collaborated to solve global health concerns using science and technology.
Latest News
Danish pharmaceutical group Novo Nordisk plans to use 500 of its 3,000-strong sales force in the United States to promote its new obesity drug, executive vice president Jakob Riis told Reuters on Monday.
Novo AS invests in Ophhtotech Corporation for the further development of drug Fovista. In an announcement made today, Ophthotech Corporation said it was able to raise US$175 million in funding to finance the global Phase 3 clinical program of its lead medication Fovista.
